XKEM aktuel empfohlen unter:

du meinst wohl 0,027 €   ; )

sorry. Meinte natürlich 0,027...:)

ASK steht heute bei 0,017! Aber dafür gebe ich meine Aktien nicht her! Ich will die 0,018 sehen:)

ja d zieht zur zeit gar nicht mit...

denke auch das wir nächste woche noch mal was hören müssten!
ja freitag ist xkem tag :)
hat aber heute nur den halben tag offen !

schauen wir mal...

allen viel glück hier!

ich bin Bullish letzten Monat gab es die 0,034€! Das wären bei einem Einstieg zu 0,015€ über 100%. Also ich bleibe mal dabei.

gerade was, ASK schon 0,019 mein EK war 0,015 Hm... Kommen News?

finance.yahoo.com/q/is?s=xkem.ob

.......................................
That’s it... let’s make some money now!

Nachmittag!  

zu 0,005!!! :) Würde mal abwarten wie weit der Kurs rutscht. Wegen einem Teilverkauf sitze ich jetzt auf 25000Stk.

von wen man hier im Thread grüne Sterne bekommt. Hier lesen wohl einige mit...

dann wählt hier mal noch schnell fürn dr. pandey!
ist morgen zu ende und es sieht sehr gut aus fürn pandey!

www.marketwatch.com/ceooftheyear/2006/...d=djm_ceovotemktwmjr.

9831 votes hat der Xechi.

sieht gut aus!und wie gesagt heute die letzte möglichkeit noch zu wählen!


Here are the latest vote counts for all CEO's. I explained in a post two nights ago how I arrive at these numbers. Since public votes alone do not make up all the criteria, our good Dr. is not a shoe-in here, but at least he may have the popular vote.

Warren Buffett 6558 votes

John Chambers 2861 votes

Mathew Ferguson 1992 votes

Mark Hurd 2860 votes

Jeffrey Immelt 1558 votes

Steve Jobs 7291 votes

John Mack 1799 votes

Ramesh Pandey 9826 votes

James D. Sinegal 5480 votes

G. Richard Wagoner, JR. 2435 votes

www.investorshub.com/boards/read_msg.asp?message_id=15308724

schönen abend euch noch und danke für das sternchen... :)

Dr. Pandey commented, “While I am honored to have won the MarketWatch Readers’ Choice 2006 CEO of the Year Award, particularly given the impressive group of accomplished and renowned executives named as finalists for this award, what is really motivating me is how close Xechem International is to making a crucial health difference to millions of sufferers of Sickle Cell Disease, first in Nigeria, and eventually throughout the world. We have made enormous progress toward this goal in 2006, and I want to personally thank MarketWatch’s readers for recognizing my efforts by honoring me with this prestigious award. I would also like to thank each and every shareholder for their votes, support and confidence in me.”

About NICOSAN™

NICOSAN™ is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell “crises” while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby.Such forward-looking statements involve known and unknown risks and uncertainties.

Contacts:

Xechem International, Inc.
Stephen Burg, 707-425-8855
Director

HM

bei uns sind alle auf dem weihnachtsmarkt!   limi  

10th Annual
Biotech/Specialty Pharma Conference
DATE December 12–13, 2006

TIME Day One 8:30 a.m.–5:10 p.m.
Day Two 8:30 a.m.–4:30 p.m.


3:10 Xechem International, Inc. (OTCBB: XKEM)
Ramesh C. Pandey, PhD, Chairman and CEO
Xechem International, a biopharmaceutical company, is engaged in developing drugs for sickle cell disease, malaria, AIDS, and cancer from natural sources.


www.nyssa.org/...tManagement/ContentDisplay.cfm&ContentID=8897

tja, petruss,da hätteste ja mal die damen des bords als aktionär einladen können!

"New York Society of Security Analysts (NYSSA)
1177 Avenue of the Americas, 2nd Floor (between 45th and 46th Streets), NYC
Due to tight building security, all members must inform NYSSA staff of their intention to use the member facilities by 5:00 p.m. the day before you intend to visit. Please send an email to guest@nyssa.org or call our receptionist at 212-541-4530 ext. 10, specify your name, firm and time of visit. Please be prepared to show a photo ID to enter the building. "

hmmm... die sind ja vorsichtig!   limi

solche Chemieschnallen sind, lieber net. Dann lieber alle Damen von Ariva!:)